These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 17022845)

  • 1. Clinical spectrum of the osmotic-controlled release oral delivery system (OROS), an advanced oral delivery form.
    Conley R; Gupta SK; Sathyan G
    Curr Med Res Opin; 2006 Oct; 22(10):1879-92. PubMed ID: 17022845
    [TBL] [Abstract][Full Text] [Related]  

  • 2. OROS® hydromorphone in chronic pain management: when drug delivery technology matches clinical needs.
    Coluzzi F; Mattia C
    Minerva Anestesiol; 2010 Dec; 76(12):1072-84. PubMed ID: 21102402
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An extended-release formulation of oxybutynin chloride for the treatment of overactive urinary bladder.
    Goldenberg MM
    Clin Ther; 1999 Apr; 21(4):634-42. PubMed ID: 10363730
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of a new once-a-day formulation of methylphenidate for the treatment of attention-deficit/hyperactivity disorder: proof-of-concept and proof-of-product studies.
    Swanson J; Gupta S; Lam A; Shoulson I; Lerner M; Modi N; Lindemulder E; Wigal S
    Arch Gen Psychiatry; 2003 Feb; 60(2):204-11. PubMed ID: 12578439
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Single- and multiple-dose pharmacokinetics of an oral once-a-day osmotic controlled-release OROS (methylphenidate HCl) formulation.
    Modi NB; Lindemulder B; Gupta SK
    J Clin Pharmacol; 2000 Apr; 40(4):379-88. PubMed ID: 10761165
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of osmotic-controlled release oral delivery system methylphenidate HCl in adults with attention-deficit/hyperactivity disorder in Japan.
    Takahashi N; Koh T; Tominaga Y; Saito Y; Kashimoto Y; Matsumura T
    World J Biol Psychiatry; 2014 Aug; 15(6):488-98. PubMed ID: 24456065
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multisite controlled study of OROS methylphenidate in the treatment of adolescents with attention-deficit/hyperactivity disorder.
    Wilens TE; McBurnett K; Bukstein O; McGough J; Greenhill L; Lerner M; Stein MA; Conners CK; Duby J; Newcorn J; Bailey CE; Kratochvil CJ; Coury D; Casat C; Denisco MJ; Halstead P; Bloom L; Zimmerman BA; Gu J; Cooper KM; Lynch JM
    Arch Pediatr Adolesc Med; 2006 Jan; 160(1):82-90. PubMed ID: 16389216
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Randomized, Double-Blind, Placebo-Controlled Acute Comparator Trials of Lisdexamfetamine and Extended-Release Methylphenidate in Adolescents With Attention-Deficit/Hyperactivity Disorder.
    Newcorn JH; Nagy P; Childress AC; Frick G; Yan B; Pliszka S
    CNS Drugs; 2017 Nov; 31(11):999-1014. PubMed ID: 28980198
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of transitioning from extended-release methylphenidate onto osmotic, controlled-release methylphenidate in children/adolescents with ADHD: results of a 3-month non-interventional study.
    Wolff C; Alfred A; Lindermüller A; Rettig K; Mattejat F; Gerwe M; Slawik L; Schäuble B
    Curr Med Res Opin; 2011; 27 Suppl 2():35-44. PubMed ID: 21787126
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Randomized, 6-Week, Placebo-Controlled Study of Treatment for Adult Attention-Deficit/Hyperactivity Disorder: Individualized Dosing of Osmotic-Release Oral System (OROS) Methylphenidate With a Goal of Symptom Remission.
    Goodman DW; Starr HL; Ma YW; Rostain AL; Ascher S; Armstrong RB
    J Clin Psychiatry; 2017 Jan; 78(1):105-114. PubMed ID: 27487193
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative bioavailability of single-dose methylphenidate from a multilayer-release bead formulation and an osmotic system: a two-way crossover study in healthy young adults.
    Reiz JL; Donnelly GA; Michalko K
    Clin Ther; 2008 Jan; 30(1):59-69. PubMed ID: 18343243
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Single- and multiple-dose pharmacokinetics of methylphenidate administered as methylphenidate transdermal system or osmotic-release oral system methylphenidate to children and adolescents with attention deficit hyperactivity disorder.
    Pierce D; Katic A; Buckwalter M; Webster K
    J Clin Psychopharmacol; 2010 Oct; 30(5):554-64. PubMed ID: 20814325
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gastrointestinal safety of an extended-release, nondeformable, oral dosage form (OROS: a retrospective study.
    Bass DM; Prevo M; Waxman DS
    Drug Saf; 2002; 25(14):1021-33. PubMed ID: 12408733
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Osmotic Release Oral System Methylphenidate Versus Atomoxetine for the Treatment of Attention-Deficit/Hyperactivity Disorder in Chinese Youth: 8-Week Comparative Efficacy and 1-Year Follow-Up.
    Su Y; Yang L; Stein MA; Cao Q; Wang Y
    J Child Adolesc Psychopharmacol; 2016 May; 26(4):362-71. PubMed ID: 26779845
    [TBL] [Abstract][Full Text] [Related]  

  • 15. OROS-methylphenidate efficacy on specific executive functioning deficits in adults with ADHD: a randomized, placebo-controlled cross-over study.
    Bron TI; Bijlenga D; Boonstra AM; Breuk M; Pardoen WF; Beekman AT; Kooij JJ
    Eur Neuropsychopharmacol; 2014 Apr; 24(4):519-28. PubMed ID: 24508533
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety evaluation of once-daily OROS hydromorphone in patients with chronic low back pain: a pilot open-label study (DO-127).
    Wallace M; Skowronski R; Khanna S; Tudor IC; Thipphawong J
    Curr Med Res Opin; 2007 May; 23(5):981-9. PubMed ID: 17519065
    [TBL] [Abstract][Full Text] [Related]  

  • 17. OROS hydromorphone prolonged release: a review of its use in the management of chronic, moderate to severe pain.
    Carter NJ; Keating GM
    CNS Drugs; 2010 Apr; 24(4):337-61. PubMed ID: 20297858
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A prospective multicentre study to evaluate the efficacy and tolerability of osmotic release oral system (OROS) hydromorphone in opioid-naive cancer patients: Results of the Korean South West Oncology Group study.
    Song EK; Shim H; Han HS; Sun D; Lee SI; Kang MH; Lee K; Cho D; Cho IS; Park SY; Kim S; Yim CY
    Pain Res Manag; 2015; 20(6):293-9. PubMed ID: 26474382
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Plasma methylphenidate concentrations in youths treated with high-dose osmotic release oral system formulation.
    Stevens JR; George RA; Fusillo S; Stern TA; Wilens TE
    J Child Adolesc Psychopharmacol; 2010 Feb; 20(1):49-54. PubMed ID: 20166796
    [TBL] [Abstract][Full Text] [Related]  

  • 20. No Superiority of Treatment With Osmotic Controlled-Release Oral Delivery System-Methylphenidate Over Short/Medium-Acting Methylphenidate Preparations in the Rate and Timing of Injuries in Children With Attention-Deficit/Hyperactivity Disorder.
    Golubchik P; Kodesh A; Weizman A
    Clin Neuropharmacol; 2017; 40(1):11-15. PubMed ID: 27879551
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.